TGRX 3544
Alternative Names: TGRX-3544Latest Information Update: 24 Sep 2025
At a glance
- Originator Shenzhen TargetRx
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-kit modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal stromal tumours; Systemic mastocytosis
Most Recent Events
- 25 Apr 2025 Preclinical trials in Gastrointestinal stromal tumours in China (PO) prior to April 2025
- 25 Apr 2025 Preclinical trials in Systemic mastocytosis in China (PO) prior to April 2025
- 25 Apr 2025 Pharmacodynamics data from a preclinical study in gastrointestinal stromal tumours and systemic mastocytosis presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)